View Past PerformanceThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsMarrone Bio Innovations 대차대조표 건전성재무 건전성 기준 점검 2/6핵심 정보139.35%부채/자본 비율US$31.87m부채이자보상배율n/a현금US$9.36m자본US$22.87m총부채US$53.34m총자산US$76.21m최근 재무 건전성 업데이트분석 기사 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...모든 업데이트 보기Recent updatesSeeking Alpha • Jul 11Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop SolutionsMarrone Bio Innovations (NASDAQ:MBII) on Monday said its shareholders had approved the proposed merger agreement with Bioceres Crop Solutions (BIOX). BIOX and MBII announced the proposed deal in March, as per which BIOX would acquire MBII in an all-stock transaction. The companies had said that each MBII share will be exchanged at closing for BIOX shares at a fixed ratio of 0.088, representing a value of ~$236M. MBII on Monday said its shareholders met at a special shareholder meeting on July 8 and approved the proposal. MBII said the companies intend to close the deal on July 12. MBII stock -2.4% at $1.03 in morning trading, while BIOX was down 1.5% at $12.04.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 140%. Over the next year, revenue is forecast to grow 35%, compared to a 12% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to US$1.38Down from US$2.28, the current price target is an average from 2 analysts. New target price is 61% above last closing price of US$0.85. The company is forecast to post a net loss per share of US$0.058 next year compared to a net loss per share of US$0.095 last year.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.Reported Earnings • Mar 29Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$0.095 loss per share (up from US$0.14 loss in FY 2020). Revenue: US$44.3m (up 16% from FY 2020). Net loss: US$16.6m (loss narrowed 18% from FY 2020). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 27%, compared to a 13% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 18Price target decreased to US$2.14Down from US$2.43, the current price target is an average from 5 analysts. New target price is 104% above last closing price of US$1.05. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.092 next year compared to a net loss per share of US$0.14 last year.Price Target Changed • Jan 19Price target decreased to US$2.28Down from US$2.53, the current price target is an average from 5 analysts. New target price is 211% above last closing price of US$0.73. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.094 next year compared to a net loss per share of US$0.14 last year.Breakeven Date Change • Nov 25No longer forecast to breakevenThe 6 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$3.96m in 2023.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.028 loss per share (vs US$0.04 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$9.86m (up 12% from 3Q 2020). Net loss: US$4.95m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Executive Departure • Sep 09Chief Manufacturing Officer Kevin Hammill has left the companyOn the 6th of September, Kevin Hammill's tenure as Chief Manufacturing Officer ended after 3.3 years in the role. As of June 2021, Kevin still personally held 207.90k shares (US$345k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.33 years.분석 기사 • Aug 21Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) OutlookThe latest analyst coverage could presage a bad day for Marrone Bio Innovations, Inc. ( NASDAQ:MBII ), with the...Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.019 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.6m (up 3.4% from 2Q 2020). Net loss: US$3.04m (loss widened 5.7% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Price Target Changed • Aug 18Price target decreased to US$2.83Down from US$3.23, the current price target is an average from 5 analysts. New target price is 160% above last closing price of US$1.09. Stock is down 24% over the past year.Reported Earnings • May 15First quarter 2021 earnings released: US$0.019 loss per share (vs US$0.05 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$11.0m (up 14% from 1Q 2020). Net loss: US$3.26m (loss narrowed 54% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target increased to US$3.29Up from US$2.87, the current price target is an average from 5 analysts. New target price is 82% above last closing price of US$1.81. Stock is up 150% over the past year.분석 기사 • Apr 08Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near FutureMarrone Bio Innovations, Inc. ( NASDAQ:MBII ) is possibly approaching a major achievement in its business, so we would...Reported Earnings • Mar 26Full year 2020 earnings released: US$0.14 loss per share (vs US$0.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$38.4m (up 31% from FY 2019). Net loss: US$20.2m (loss narrowed 46% from FY 2019). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.분석 기사 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Executive Departure • Feb 24President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.Executive Departure • Feb 19President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.분석 기사 • Feb 15What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?Every investor in Marrone Bio Innovations, Inc. ( NASDAQ:MBII ) should be aware of the most powerful shareholder...Price Target Changed • Feb 13Price target raised to US$2.32Up from US$2.01, the current price target is an average from 6 analysts. The new target price is 13% below the current share price of US$2.65. As of last close, the stock is up 115% over the past year.Is New 90 Day High Low • Feb 03New 90-day high: US$1.73The company is up 49% from its price of US$1.16 on 04 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.90 per share.분석 기사 • Jan 25Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price GainWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...Is New 90 Day High Low • Jan 16New 90-day high: US$1.53The company is up 33% from its price of US$1.15 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.84 per share.분석 기사 • Jan 04When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?We feel now is a pretty good time to analyse Marrone Bio Innovations, Inc.'s ( NASDAQ:MBII ) business as it appears the...Is New 90 Day High Low • Dec 11New 90-day high: US$1.34The company is up 18% from its price of US$1.14 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$8.10 per share.분석 기사 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyst Estimate Surprise Post Earnings • Nov 11Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 41%. Over the next year, revenue is forecast to grow 47%, compared to a 3.3% growth forecast for the Chemicals industry in the US.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.04 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$8.83m (up 27% from 3Q 2019). Net loss: US$6.06m (loss narrowed 63% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.재무 상태 분석단기부채: MBII 의 단기 자산 ( $33.0M )은 단기 부채( $41.7M ).장기 부채: MBII의 단기 자산($33.0M)이 장기 부채($11.6M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: MBII 의 순부채 대 자기자본 비율( 98.4% )은 높음으로 간주됩니다.부채 감소: MBII는 5년 전 마이너스 주주 지분이었으나 현재 플러스로 개선되었습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: MBII 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 11.3 %의 역사적 비율로 계속 증가할 경우 MBII 의 현금 활주로는 1년 미만입니다.건전한 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/07/13 04:52종가2022/07/12 00:00수익2022/03/31연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Marrone Bio Innovations, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nathan WeinsteinAegis Capital CorporationBenjamin KalloBairdRobert BurlesonCanaccord Genuity6명의 분석가 더 보기
분석 기사 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jul 11Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop SolutionsMarrone Bio Innovations (NASDAQ:MBII) on Monday said its shareholders had approved the proposed merger agreement with Bioceres Crop Solutions (BIOX). BIOX and MBII announced the proposed deal in March, as per which BIOX would acquire MBII in an all-stock transaction. The companies had said that each MBII share will be exchanged at closing for BIOX shares at a fixed ratio of 0.088, representing a value of ~$236M. MBII on Monday said its shareholders met at a special shareholder meeting on July 8 and approved the proposal. MBII said the companies intend to close the deal on July 12. MBII stock -2.4% at $1.03 in morning trading, while BIOX was down 1.5% at $12.04.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 140%. Over the next year, revenue is forecast to grow 35%, compared to a 12% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$1.38Down from US$2.28, the current price target is an average from 2 analysts. New target price is 61% above last closing price of US$0.85. The company is forecast to post a net loss per share of US$0.058 next year compared to a net loss per share of US$0.095 last year.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.
Reported Earnings • Mar 29Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$0.095 loss per share (up from US$0.14 loss in FY 2020). Revenue: US$44.3m (up 16% from FY 2020). Net loss: US$16.6m (loss narrowed 18% from FY 2020). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 27%, compared to a 13% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 18Price target decreased to US$2.14Down from US$2.43, the current price target is an average from 5 analysts. New target price is 104% above last closing price of US$1.05. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.092 next year compared to a net loss per share of US$0.14 last year.
Price Target Changed • Jan 19Price target decreased to US$2.28Down from US$2.53, the current price target is an average from 5 analysts. New target price is 211% above last closing price of US$0.73. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.094 next year compared to a net loss per share of US$0.14 last year.
Breakeven Date Change • Nov 25No longer forecast to breakevenThe 6 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$3.96m in 2023.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.028 loss per share (vs US$0.04 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$9.86m (up 12% from 3Q 2020). Net loss: US$4.95m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Executive Departure • Sep 09Chief Manufacturing Officer Kevin Hammill has left the companyOn the 6th of September, Kevin Hammill's tenure as Chief Manufacturing Officer ended after 3.3 years in the role. As of June 2021, Kevin still personally held 207.90k shares (US$345k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.33 years.
분석 기사 • Aug 21Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) OutlookThe latest analyst coverage could presage a bad day for Marrone Bio Innovations, Inc. ( NASDAQ:MBII ), with the...
Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.019 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.6m (up 3.4% from 2Q 2020). Net loss: US$3.04m (loss widened 5.7% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Price Target Changed • Aug 18Price target decreased to US$2.83Down from US$3.23, the current price target is an average from 5 analysts. New target price is 160% above last closing price of US$1.09. Stock is down 24% over the past year.
Reported Earnings • May 15First quarter 2021 earnings released: US$0.019 loss per share (vs US$0.05 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$11.0m (up 14% from 1Q 2020). Net loss: US$3.26m (loss narrowed 54% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target increased to US$3.29Up from US$2.87, the current price target is an average from 5 analysts. New target price is 82% above last closing price of US$1.81. Stock is up 150% over the past year.
분석 기사 • Apr 08Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near FutureMarrone Bio Innovations, Inc. ( NASDAQ:MBII ) is possibly approaching a major achievement in its business, so we would...
Reported Earnings • Mar 26Full year 2020 earnings released: US$0.14 loss per share (vs US$0.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$38.4m (up 31% from FY 2019). Net loss: US$20.2m (loss narrowed 46% from FY 2019). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
분석 기사 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Executive Departure • Feb 24President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.
Executive Departure • Feb 19President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.
분석 기사 • Feb 15What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?Every investor in Marrone Bio Innovations, Inc. ( NASDAQ:MBII ) should be aware of the most powerful shareholder...
Price Target Changed • Feb 13Price target raised to US$2.32Up from US$2.01, the current price target is an average from 6 analysts. The new target price is 13% below the current share price of US$2.65. As of last close, the stock is up 115% over the past year.
Is New 90 Day High Low • Feb 03New 90-day high: US$1.73The company is up 49% from its price of US$1.16 on 04 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.90 per share.
분석 기사 • Jan 25Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price GainWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...
Is New 90 Day High Low • Jan 16New 90-day high: US$1.53The company is up 33% from its price of US$1.15 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.84 per share.
분석 기사 • Jan 04When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?We feel now is a pretty good time to analyse Marrone Bio Innovations, Inc.'s ( NASDAQ:MBII ) business as it appears the...
Is New 90 Day High Low • Dec 11New 90-day high: US$1.34The company is up 18% from its price of US$1.14 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$8.10 per share.
분석 기사 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analyst Estimate Surprise Post Earnings • Nov 11Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 41%. Over the next year, revenue is forecast to grow 47%, compared to a 3.3% growth forecast for the Chemicals industry in the US.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.04 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$8.83m (up 27% from 3Q 2019). Net loss: US$6.06m (loss narrowed 63% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.